GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iZafe Group AB (OSTO:IZAFE B) » Definitions » Cyclically Adjusted Price-to-FCF

iZafe Group AB (OSTO:IZAFE B) Cyclically Adjusted Price-to-FCF : (As of Jul. 05, 2025)


View and export this data going back to 2011. Start your Free Trial

What is iZafe Group AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


iZafe Group AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for iZafe Group AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iZafe Group AB Cyclically Adjusted Price-to-FCF Chart

iZafe Group AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

iZafe Group AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of iZafe Group AB's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, iZafe Group AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iZafe Group AB's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where iZafe Group AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

iZafe Group AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

iZafe Group AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, iZafe Group AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.023/132.8245*132.8245
=-0.023

Current CPI (Mar. 2025) = 132.8245.

iZafe Group AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.000 100.225 0.000
201506 0.000 99.995 0.000
201512 0.000 100.276 0.000
201603 0.000 100.751 0.000
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 -0.070 102.022 -0.091
201706 -0.073 102.752 -0.094
201709 -0.112 103.279 -0.144
201712 -0.062 103.793 -0.079
201803 -0.121 103.962 -0.155
201806 -0.035 104.875 -0.044
201809 0.017 105.679 0.021
201812 -0.036 105.912 -0.045
201903 -0.108 105.886 -0.135
201906 -0.738 106.742 -0.918
201909 -0.230 107.214 -0.285
201912 0.170 107.766 0.210
202003 -0.240 106.563 -0.299
202006 -0.075 107.498 -0.093
202009 -0.222 107.635 -0.274
202012 -0.180 108.296 -0.221
202103 -0.219 108.360 -0.268
202106 -0.203 108.928 -0.248
202109 -0.179 110.338 -0.215
202112 -0.178 112.486 -0.210
202203 -0.085 114.825 -0.098
202206 -0.081 118.384 -0.091
202209 -0.053 122.296 -0.058
202212 -0.056 126.365 -0.059
202303 -0.024 127.042 -0.025
202306 -0.009 129.407 -0.009
202309 -0.011 130.224 -0.011
202312 -0.008 131.912 -0.008
202403 -0.016 132.205 -0.016
202406 -0.016 132.716 -0.016
202409 -0.011 132.304 -0.011
202412 -0.001 132.987 -0.001
202503 -0.023 132.825 -0.023

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


iZafe Group AB  (OSTO:IZAFE B) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


iZafe Group AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of iZafe Group AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


iZafe Group AB Business Description

Traded in Other Exchanges
Address
David Bagares Gata 3, Stockholm, SWE, 111 38
iZafe Group AB is a pure Life-Science company engaged in the development of digital drug dispensing. The company conducts research, development and marketing of digital medical solutions and services for safer drug management at home. iZafe's drug robot Dosell is used to reduce the risk of incorrect medication at home, relieve public care, increase the patient's quality of life and create a safer environment for relatives. The customers consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe sells through well-established partners who already have long and deep customer relationships with the priority customer groups.

iZafe Group AB Headlines

No Headlines